Attached files
| file | filename |
|---|---|
| EX-31.2 - RULE 13A-14(A) CERTIFICATION CFO - Arcutis Biotherapeutics, Inc. | exhibit312cfoq42020.htm |
| EX-31.1 - RULE 13A-14(A) CERTIFICATION CEO - Arcutis Biotherapeutics, Inc. | exhibit311ceoq42020.htm |
| EX-23.1 - AUDITOR'S CONSENT - Arcutis Biotherapeutics, Inc. | auditorsconsent.htm |
| EX-10.25 - INTERQUIM SUPPLY AGREEMENT - Arcutis Biotherapeutics, Inc. | arcutis-interquimapisupply.htm |
| EX-10.24 - SEVERANCE AND CHANGE IN CONTROL AGREEMENT - MATTHEW MOORE - Arcutis Biotherapeutics, Inc. | severanceandchangeincontro.htm |
| EX-10.23 - OFFER OF EMPLOYMENT - MATTHEW MOORE - Arcutis Biotherapeutics, Inc. | offerofemployment-matthewm.htm |
| 10-K - 10-K - Arcutis Biotherapeutics, Inc. | arqt-20201231.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Arcutis Biotherapeutics, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Todd Franklin Watanabe, Chief Executive Officer of the Company, and John W. Smither, Chief Financial Officer of the Company, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: February 16, 2021 | By: | /s/ Todd Franklin Watanabe | ||||||
Todd Franklin Watanabe President, Chief Executive Officer and Director (Principal Executive Officer) | ||||||||
Date: February 16, 2021 | By: | /s/ John W. Smither | ||||||
John W. Smither Chief Financial Officer (Principal Accounting and Financial Officer) | ||||||||